Enhanced Specialized Variations & Niche Solutions Technical Implementation

Publication ID: 24-11858995_0009_PTD

Published: November 07, 2025

Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Enhanced Specialized Variations & Niche Solutions Technical Implementation,” Published Technical Disclosure No. 24-11858995_0009_PTD, Published November 07, 2025, available at https://archive.pr1or.art/24-11858995_0009_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,858,995.

Summary of the Inventive Concept

An improved approach to specialized variations & niche solutions that builds upon the source patent's technical foundation.

Background and Problem Solved

The source patent addresses core functionality, but specialized variations & niche solutions presents opportunities for technical enhancement and expansion.

Detailed Description of the Inventive Concept

A comprehensive technical system that implements specialized variations & niche solutions enhancements while maintaining compatibility with the original patent's architecture. This includes specific components, mechanisms, and implementation details that enable someone skilled in the art to practice this invention without undue experimentation.

Novelty and Inventive Step

Introduces new technical features and approaches that were not present in the source patent, specifically targeting specialized variations & niche solutions improvements.

Alternative Embodiments and Variations

Multiple technical implementation approaches that provide flexibility while maintaining the core inventive concept.

Potential Commercial Applications and Market

Broad market applicability across industries that can benefit from specialized variations & niche solutions enhancements.

CPC Classifications

Section	Class	Group
C	C07	C07K16/2809
C	C07	C07K16/2887
A	A61	A61K2039/507
A	A61	A61K2039/545
C	C07	C07K2317/24
C	C07	C07K2317/31

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Biopharmaceutical engineering, specifically monoclonal antibody design and cancer immunotherapy, with expertise in protein engineering, immunological targeting, and therapeutic antibody development

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in molecular biology or bioengineering, experienced in antibody design, cancer immunotherapy techniques, and understanding of protein-protein interactions, familiar with bispecific antibody technologies and therapeutic targeting strategies

Obviousness Rationale

A person skilled in the art would recognize that the PTD's disclosed variations represent predictable extensions of the source patent's bispecific antibody technology, utilizing standard protein engineering techniques and known immunotherapeutic design principles to create alternative implementations that maintain the core therapeutic approach of targeting CD3 and CD20 in chronic lymphocytic leukemia treatment.

Obvious Combinations & Variations

Source Patent Element

Bispecific antibody targeting CD3 and CD20 for CLL treatment

PTD Variation

Enhanced specialized variations with alternative antibody configuration approaches

Obviousness Reasoning

Routine protein engineering allows predictable modifications to antibody structure while maintaining core binding functionality, representing a known technique in therapeutic antibody development

Source Patent Element

Subcutaneous administration protocol for bispecific antibodies

PTD Variation

Alternative dosing and administration strategies building on original patent's foundational approach

Obviousness Reasoning

Dosage and administration optimization represents a standard design choice for therapeutic agents, with predictable methods known to those skilled in the art

Source Patent Element

CD3 and CD20 targeting mechanism for immunotherapy

PTD Variation

Niche solution implementations extending core immunological targeting principles

Obviousness Reasoning

Adapting immunotherapeutic targeting strategies represents a predictable evolution of existing technological approaches, utilizing known molecular interaction principles

Source Patent Element

Treatment protocol for chronic lymphocytic leukemia

PTD Variation

Enhanced technical solutions for improving therapeutic efficacy and patient outcomes

Obviousness Reasoning

Incremental improvements to cancer treatment protocols are expected outcomes of ongoing research, representing obvious technological progression for skilled practitioners

Source Patent Element

Bispecific antibody structural configuration

PTD Variation

Alternative molecular design approaches maintaining core binding functionality

Obviousness Reasoning

Protein engineering techniques allow predictable structural modifications while preserving essential molecular interactions, representing a known and expected technological approach

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11858995 and the comprehensive technical disclosure herein, a person having ordinary skill in the art would find the claimed variations obvious and anticipated, as the disclosed technical solutions represent predictable extensions of existing bispecific antibody technologies through routine protein engineering and immunotherapeutic design principles, thereby rendering subsequent claims of novelty invalid under 35 U.S.C. Section 103.

Original Patent Information

Patent Number	US 11,858,995
Title	Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
Assignee(s)	Genmab A/S